Literature DB >> 21571656

Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer.

Anna Rita Larici1, Annemilia del Ciello, Fabio Maggi, Silvia Immacolata Santoro, Bruno Meduri, Vincenzo Valentini, Alessandro Giordano, Lorenzo Bonomo.   

Abstract

Three-dimensional (3D) conformal radiation therapy (CRT) and stereotactic body radiation therapy (SBRT) are designed to deliver the maximum therapeutic radiation dose to the tumor, allowing improved local disease control, while minimizing irradiation of surrounding normal structures. The complex configuration of the multiple beams that deliver the radiation dose to the tumor in 3D CRT and SBRT produces patterns of lung injury that differ in location and extent from those seen after conventional radiation therapy. Radiation-induced changes in lung tissue after 3D CRT and SBRT occur within the radiation portals. The imaging appearance of irradiated tissues varies according to the time elapsed after the completion of therapy, with acute-phase changes of radiation pneumonitis represented by ground-glass opacities and consolidation and with late-phase changes of radiation fibrosis manifesting as volume loss, consolidation, and traction bronchiectasis. Knowledge of treatment timelines and radiation field locations, as well as familiarity with the full spectrum of possible radiation-induced lung injuries after 3D CRT and SBRT, is important to correctly interpret the abnormalities that may be seen at computed tomography (CT). Differential diagnoses in this context might include infections, lymphangitic carcinomatosis, local recurrence of malignancy, and radiation-induced tumors. The integration of morphologic information obtained at CT with metabolic information obtained at positron emission tomography is helpful in distinguishing radiation-induced parenchymal abnormalities from residual, recurrent, and new cancers. Thus, multimodality follow-up imaging may lead to substantial changes in disease management.
Copyright © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571656     DOI: 10.1148/rg.313105096

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  28 in total

Review 1.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

2.  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

Authors:  David E Gerber; James J Urbanic; Corey Langer; Chen Hu; I-Fen Chang; Bo Lu; Benjamin Movsas; Robert Jeraj; Walter J Curran; Jeffrey D Bradley
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

Review 3.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

4.  Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology.

Authors:  J de Castro; M Cobo; D Isla; J Puente; N Reguart; B Cabeza; A Gayete; M Sánchez; M I Torres; J Ferreirós
Journal:  Clin Transl Oncol       Date:  2014-11-06       Impact factor: 3.405

5.  Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy.

Authors:  Darragh Halpenny; Carole A Ridge; Sara Hayes; Junting Zheng; Chaya S Moskowitz; Andreas Rimner; Michelle S Ginsberg
Journal:  Clin Imaging       Date:  2014-12-12       Impact factor: 1.605

6.  Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.

Authors:  Mamta Singhvi; Percy Lee
Journal:  BMJ Case Rep       Date:  2013-01-22

Review 7.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

8.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Authors:  Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn
Journal:  Cancer Discov       Date:  2017-09-24       Impact factor: 39.397

9.  Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC).

Authors:  Rezarta Frakulli; Fabrizio Salvi; Damiano Balestrini; Marcella Palombarini; Ilir Akshija; Silvia Cammelli; Alessio Giuseppe Morganti; Maurizio Zompatori; Giovanni Frezza
Journal:  Transl Lung Cancer Res       Date:  2017-12

10.  Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy.

Authors:  Carole Dennie; Rebecca Thornhill; Carolina A Souza; Cecilia Odonkor; Jason R Pantarotto; Robert MacRae; Graham Cook
Journal:  Quant Imaging Med Surg       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.